Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Allogene Therapeutics (ALLO) over the last 6 years, with Sep 2025 value amounting to $222.0 million.

  • Allogene Therapeutics' Shares Outstanding (Diluted Average) rose 6.14% to $222.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.0 million, marking a year-over-year increase of 6.14%. This contributed to the annual value of $194.8 million for FY2024, which is 24.14% up from last year.
  • Per Allogene Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $222.0 million for Q3 2025, which was up 1.42% from $218.9 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $222.0 million in Q3 2025 and a low of $132.2 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $190.0 million (2024), whereas its average is $185.0 million.
  • Data for Allogene Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY rose of 29.45% (in 2024) over the last 5 years.
  • Over the past 5 years, Allogene Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $135.8 million in 2021, then grew by 5.39% to $143.1 million in 2022, then rose by 9.63% to $156.9 million in 2023, then increased by 24.14% to $194.8 million in 2024, then increased by 6.14% to $222.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $222.0 million in Q3 2025, compared to $218.9 million in Q2 2025 and $215.4 million in Q1 2025.